Hear how Beth was able to get back to living after her stage III CRC treatment
Discover our BESPOKE study of ctDNA-guided therapy for colorectal cancer
Do you want to be a part of something extraordinary? Join Natera’s BESPOKE CRC study to make a difference for individuals who, like you, have been diagnosed with colorectal cancer (CRC). The study will examine the use of Signatera™ and the impact it has on treatment decisions for clinical outcomes in patients with stage II and III colorectal cancer. The study will enroll at least one thousand patients. Natera and its collaborators will collect data on clinical decisions, benefits, and outcomes from enrolled patients for two years. Participants may receive up to $150 dollars for their time.
Visit our Signatera™ BESPOKE study page to learn more about participating in the clinical study.
How is the Signatera™ test performed?
Personalized, tumor-informed assay
One-time, primary tissue sample and matched normal tissue is required for whole exome sequencing and personalized test design.
Ultrasensitive ctDNA detection
Signatera™ is designed to detect ctDNA of somatic and truncal variants to optimize sensitivity. Tumor-informed method enables filtering of CHIP mutations to decrease false positive rates.
Optimized for longitudinal monitoring
Once the patient’s personalized test has been designed, only a blood sample is needed each subsequent time Signatera™ is ordered for the program or Surveillance program.
Peace of mind powered by Signatera™
Helping Patients Make Informed Decisions
For patients undergoing treatment for colon cancer, each scan can be a scary experience. Wondering if the treatments are working and the nagging fear of colorectal cancer recurrence can cause a great deal of anxiety and worry.
Signatera™ can help alleviate these concerns by making it much easier for doctors to assess response to treatment and watch for the earliest warning signs of recurrence. It is designed to detect molecular residual disease by looking for the distinct tumor DNA in each patient. This personalized, tumor-informed assay is optimized to provide accurate detection for each individual, making it a powerful source of information to help guide future care decisions.
Questions regarding coverage?